Syndax Pharmaceuticals announced that results from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (cGVHD), will be featured during the Plenary Scientific Session at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023, in San Diego, California. Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further highlight revumenib's potential best-in-class profile. 100% ORR (n=7) and manageable safety profile observed in Phase 1 results of SAVE trial, an all-oral combination regimen of revumenib plus venetoclax-decitabine/cedazuridine in R/R AML.

Patients re-started on treatment with revumenib in post-transplant maintenance exhibit durable MRD negative responses.